



Physiomics Plc
The Magdalen Centre
The Oxford Science Park
Robert Robinson Avenue
Oxford
OX4 4GA
UK

5 August 2019

Physiomics plc
("Physiomics") or (the "Company")

Director Dealing

The Company announces that it received notice today that the following Directors acquired the following number of ordinary shares in the Company at the following prices per share:

Director	Number of shares acquired	Acquisition price per share
Dr C Chassagnole	100,000	3.38p

Following the sales of shares, the total holdings of Dr Chassagnole will be 517,008 ordinary shares.

The total number of shares in issue remains 71,910,394 ordinary shares. There are no shares held in treasury. This total voting rights figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interests in, or a change to their interest in, Physiomics under the Disclosure and Transparency Rules.

Enquiries:

Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980

Strand Hanson Ltd (NOMAD)
Richard Tulloch & James Dance
+44 (0) 20 7409 3494

Hybridan LLP (Broker)

Claire Louise Noyce
+44 (0) 20 3764 2341

Notes to Editor

About Physiomics

Physiomics plc (AIM: PYC) is a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry. The Company's Virtual Tumour™ technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics' technologies have been confirmed by over 70 projects, involving over 30 targets and 60 drugs, and has worked with clients such as Merck KGaA, Merck & Co, Bayer and Lilly.

Based in Oxford UK, the Company works with clients worldwide to support their pre-clinical and clinical oncology development programs. Its team of scientists and computer modelling experts provide bespoke solutions encompassing data, analytics and insight.

Physiomics senior management has academic and commercial expertise, including over 120 years collectively of working in oncology and/or computational biology and over 120 publications in peer reviewed journals that have attracted thousands of citations.

The information contained within this announcement is deemed by the Company to constitute inside information under the Market Abuse Regulation (EU) No. 596/2014.

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1	Details of the person discharging managerial responsibilities/person closely associated	
a)	Name	Christophe Chassagnole
2	Reason for the notification	
a)	Position/status	Director, COO
b)	Initial notification/ Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	Physiomics plc
b)	LEI	213800A71DSZ6ABMTQ91
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
a)	Description of the financial instrument, type of instrument	Ordinary share
	Identification code	GB00BDR6W943
b)	Nature of the transaction	Acquisition of shares

c)	Price(s) and volume(s)	Price(s)	Volume(s)
		3.38p	100,000
d)	Aggregated information - Aggregated volume - Price	100,000 At 3.38p	
e)	Date of the transaction	02-08-2019	
f)	Place of the transaction	XLON, AIM	